Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 8:28 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 13,937 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Trial Clear all

Conditions: Obesity, Obesity, Abdominal, Metabolic Syndrome, Weight Loss
Interventions: Vestibular nerve stimulator, Sham vestibular stimulation; Device
Lead sponsor: Neurovalens Ltd.; Industry
Eligibility: 22 Years to 80 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: San Diego, California

Conditions: Motor Vehicle Accident, Interaction, Parent-Offspring
Interventions: Hazard Anticipation Program for Parents of Teen Drivers; Behavioral
Lead sponsor: Elizabeth O'Neal; Other
Eligibility: 14 Years and older
Enrollment: 103 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Peripheral Arterial Disease
Interventions: Placebo + background APT + SMT, Vorapaxar 2.08 mg/d + background APT + SMT.; Drug
Lead sponsor: North Texas Veterans Healthcare System; Federal
Eligibility: 40 Years to 90 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 12
States / cities: Tucson, Arizona • San Diego, California • Denver, Colorado + 8 more

Conditions: Head Cancer, Neck Cancer, Pain
Interventions: Transcutaneous Electrical Nerve Stimulation (TENS); Device
Lead sponsor: Jennifer E. Lee; Other
Eligibility: 18 Years to 90 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Frontal Fibrosing Alopecia
Interventions: Delgocitinib cream, Delgocitinib cream vehicle; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Burlington, Massachusetts

Conditions: Cytomegalovirus (CMV), HIV (Human Immunodeficiency Virus)
Interventions: VIR-1388, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Birmingham, Alabama • Boston, Massachusetts

Conditions: Diabetes Mellitus
Interventions: individualized insulin sensitivity index (ISind); Other
Lead sponsor: Yale University; Other
Eligibility: 12 Years to 21 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Mammaplasty
Interventions: Breast Reconstruction (Mammaplasty), Pecs blocks, Exparel, Bupivacaine; Procedure · Device · Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Ovarian Cancer, Endometrial Cancer, Fallopian Cancer, Peritoneal Cancer
Interventions: E39 peptide (100mcg)/GM-CSF vaccine plus E39 booster, Non-vaccine clinically matched control group, E39 peptide (500mcg)/GM-CSF vaccine plus E39 booster, E39 peptide (1000mcg)/GM-CSF vaccine plus E39 booster, E39 peptide (100mcg)/GM-CSF vaccine plus J65 booster, E39 peptide (500mcg)/GM-CSF vaccine plus J65 booster, E39 peptide (1000mcg)/GM-CSF vaccine plus J65 booster; Biological · Other
Lead sponsor: COL George Peoples, MD, FACS; Federal
Eligibility: 18 Years and older · Female only
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Annandale, Virginia

Conditions: Malaria
Interventions: DM1157, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Myocardial Infarction, Cardiovascular Death, Atherothrombosis, Stroke
Interventions: Ticagrelor 90 mg, Ticagrelor 60 mg, Ticagrelor Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 50 Years to 130 Years
Enrollment: 21,379 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 250
States / cities: Alexander City, Alabama • Athens, Alabama • Birmingham, Alabama + 247 more

Conditions: Pain, Postoperative, Major Abdominal Surgery
Interventions: TAP block, Epidural analgesia, EXPAREL, Bupivacaine; Procedure · Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 85 Years
Enrollment: 514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 2
States / cities: Cleveland, Ohio

Conditions: Chronic Pelvic Pain, Depression, Inflammation Pelvic
Interventions: Mindfulness based stress reduction, Healthy Lifestyle; Behavioral
Lead sponsor: University of Missouri, Kansas City; Other
Eligibility: 21 Years to 50 Years · Female only
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Antibiotic Prophylaxis Surgery
Interventions: CeFAZolin 1000 MG, Saline (0.9%, sterile, for infusion); Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Somerset, New Jersey

Conditions: HIV Infections
Interventions: DNA Nat-B env, DNA CON-S env, DNA Mosaic env, MVA-CMDR, Placebo for DNA Nat-B env, Placebo for DNA CON-S env, Placebo for DNA Mosaic env, Placebo for MVA-CMDR; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2020
U.S. locations: 6
States / cities: Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 2 more

Conditions: Metabolic Syndrome X, Prediabetic State, Insulin Resistance, Obesity, Metabolic Diseases
Interventions: Chromium picolinate; Drug
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hemiplegia, Cerebral Palsy, Children
Interventions: HABIT; Behavioral
Lead sponsor: Teachers College, Columbia University; Other
Eligibility: 18 Months to 16 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer
Interventions: tarenflurbil, adjuvant therapy; Drug · Procedure
Lead sponsor: Myrexis Inc.; Industry
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 58
States / cities: Homewood, Alabama • Anchorage, Alaska • Fresno, California + 49 more

Conditions: Critical Illness, Communication Disabilities
Interventions: EMPOWER, Enhanced Usual Care; Behavioral · Other
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2023
U.S. locations: 3
States / cities: Flushing, New York • New York, New York

Conditions: Pain
Interventions: Bupivacaine, Saline; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 100 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Angina Pectoris
Interventions: Osteopathic manipulation; Procedure
Lead sponsor: University of New England; Other
Eligibility: 18 Years to 81 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Saco, Maine

Conditions: Arthritis, Psoriatic
Interventions: golimumab, Placebo; golimumab; Biological
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 407 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 18
States / cities: Huntsville, Alabama • La Jolla, California • Upland, California + 15 more

Conditions: Parkinson's Disease
Interventions: Rasagiline, Placebo; Drug
Lead sponsor: University of Florida; Other
Eligibility: 40 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 3
States / cities: Aurora, Colorado • Gainesville, Florida • Cleveland, Ohio

Conditions: Prostate Cancer, Venous Thromboembolism, Lymphocele After Surgical Procedure, Deep Venous Thrombosis, Pulmonary Embolism
Interventions: Subcutaneous Heparin; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 501 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Vestibular Stimulation to Trigger Adipose Loss Clinical Trial

Hazard Anticipation Program for Parents of Teen Drivers

Excellence In Peripheral Artery Disease Thrombin Receptor Antagonist Intervention In Claudication Evaluation (XLPAD-TRACE Trial)

Transcutaneous Electrical Nerve Stimulation (TENS) and Head and Neck Cancer Pain (HNC) (TENS & HNC)

A Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing Alopecia

A Clinical Study to Evaluate the Safety and Immunogenicity of a Higher Dose of the Study Vaccine, VIR-1388, in HCMV-seropositive Adult Participants Without HIV

A New Wizard for Insulin Sensitivity Estimation From SAP: a Randomized Controlled Trial in Adolescents With T1D

The Use of Pecs Blocks in Combination With Exparel in Breast Reconstruction Surgery

Phase I/IIa Trial of Folate Binding Protein Vaccine in Ovarian Cancer

Safety and Pharmacokinetics Study of DM1157 to Treat Malaria

Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

Bilateral Transversus Abdominis Plane Block With Exparel Verus Continuous Epidural Analgesia With Bupivacaine

MOCHI: An RCT of Mindfulness as Treatment for Chronic Pelvic Pain in AD Women

Efficacy and Safety of Intraosseous Antibiotic Prophylaxis in Total Hip Replacement

Evaluating the Safety and Immune Response to Three Different DNA HIV Vaccines Administered With a MVA-CMDR Boost Vaccine in Healthy, HIV-Uninfected Adults

Chromium Picolinate for the Treatment of Metabolic Syndrome

Bimanual Training in Children With Hemiplegia

R-Flurbiprofen in Treating Patients With Localized Prostate Cancer at Risk of Recurrence

Enhancing & Mobilizing the POtential for Wellness & Emotional Resilience Among Surrogate Decision-Makers of ICU Patients

Bupivacaine Pain Pumps to Decrease Mastectomy Post-Operative Pain

Study of Osteopathic Manipulation in the Management of Angina

A Study of the Safety and Efficacy of Golimumab in Patients With Active Psoriatic Arthritis

Rasagiline for the Symptomatic Treatment of Fatigue in Parkinson's Disease

PREvention of VENous ThromboEmbolism Following Radical Prostatectomy